Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
出版年份 2013 全文链接
标题
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 15, Issue 8, Pages 737-749
出版商
Wiley
发表日期
2013-02-23
DOI
10.1111/dom.12085
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
- (2012) Vanita R. Aroda et al. CLINICAL THERAPEUTICS
- GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
- (2012) Dhanwantee Mundil et al. Diabetes & Vascular Disease Research
- Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
- (2012) M. Diamant et al. DIABETES CARE
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
- (2012) Matteo Monami et al. Experimental Diabetes Research
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- The effect of glucagon-like peptide 1 on cardiovascular risk
- (2012) Jacob Sivertsen et al. Nature Reviews Cardiology
- Cardiovascular Effects of Glucagonlike peptide–1 Agonists
- (2011) Michael H. Davidson AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
- (2011) Matteo Monami et al. Experimental Diabetes Research
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Control metabólico y pérdida de peso en pacientes con obesidad y diabetes mellitus tipo 2 tratados con exenatida
- (2011) Pedro Pujante Alarcón et al. MEDICINA CLINICA
- Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
- (2010) Caroline M. Apovian et al. AMERICAN JOURNAL OF MEDICINE
- Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
- (2010) Mads Halbirk et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
- (2010) E. S. Horton et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
- (2010) J. Liutkus et al. DIABETES OBESITY & METABOLISM
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
- (2010) P. Anagnostis et al. DIABETES OBESITY & METABOLISM
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
- Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
- (2009) T. Okerson et al. AMERICAN JOURNAL OF HYPERTENSION
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
- (2009) Kunio Hirata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study*
- (2009) Stephen Jones et al. CURRENT MEDICAL RESEARCH AND OPINION
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
- (2009) D. I. Brixner et al. DIABETES OBESITY & METABOLISM
- Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
- (2009) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study
- (2009) Jeronimo Jurado et al. Journal of the American Academy of Nurse Practitioners
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome
- (2009) Kevin D. Laugero et al. Metabolic Syndrome and Related Disorders
- Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
- (2009) Kristopher C. Dozier et al. PEPTIDES
- Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes
- (2008) Antonio Cervera et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
- (2008) Adil E. Bharucha et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat
- (2008) Indu Poornima et al. Circulation-Heart Failure
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart
- (2007) David P. Sonne et al. REGULATORY PEPTIDES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started